Medicinal marijuana use: Experiences of people with multiple sclerosis

Canadian Family Physician

Volumn 52, Issue JAN., 2006, Pages 64-65

  Page, Stacey A ^a   Verhoef, Marja J ^a  

^a UNIVERSITY OF CALGARY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CANNABIS;

ADULT; ANALGESIA; ARTICLE; BALANCE DISORDER; BLADDER DISEASE; CLINICAL ARTICLE; COGNITIVE DEFECT; DATA ANALYSIS; DRINKING BEHAVIOR; DRUG COST; DRUG EFFICACY; DRUG SAFETY; DRUG USE; ENTEROPATHY; FATIGUE; FEEDING BEHAVIOR; FEMALE; HUMAN; INTERVIEW; LEGAL ASPECT; MALE; MULTIPLE SCLEROSIS; MUSCLE SPASM; NAUSEA; PARESTHESIA; PATIENT ATTITUDE; PERSONAL EXPERIENCE; POSTAL MAIL; QUALITATIVE RESEARCH; RISK BENEFIT ANALYSIS; SEXUAL FUNCTION; SLEEP DISORDER; SMOKING; SOCIAL ASPECT; TREMOR; WRITING;

ADULT; CANADA; CANNABINOIDS; CROSS-SECTIONAL STUDIES; FEMALE; HEALTH SURVEYS; HUMANS; MALE; MARIJUANA SMOKING; MIDDLE AGED; MULTIPLE SCLEROSIS; PLANT COMPONENTS; RISK FACTORS; TREATMENT OUTCOME;

EID: 33744500730     PISSN: 0008350X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Ogborne AC, Smart RG, Weber T, Birchmore-Timney C. Who is using cannabis as a medicine and why: and exploratory study. J Psychoactive Drugs 2000;32(4)4:35-43.
2. Vincent C, Furnham A. Why do patients turn to complementary medicine? An empirical study. Br J Clin Psychol 1996;35:37-48.
3. Weiner HL. A 21 point unifying hypothesis on the etiology and treatment of multiple sclerosis. Can J Neurol Sci 1998:25(2):93-101.
4. Evans CF, Shriver LP. Multiple sclerosis: emerging opportunities for therapeutic intervention. Curr Drug Target CNS Neurol Disord 2002;1:17-30.
5. Rudick RA. Disease-modifying drugs for relapsing-remitting multiple sclerosis and future directions for multiple sclerosis therapeutics. Arch Neurol 1999;56:1079-84.
6. Ogborne AC, Smart RG, Adlaf F.M. Self-reported medical use of marijuana: a survey of the general population. CMAJ 2000:162:1685-6.
7. Clark AJ, Ware MA. Yazer E, Murray TJ, Lynch ME. Patterns of cannabis use among patients with multiple sclerosis. Neurology 2004,61(11):2098-100.
8. Page SA, Verhoef MJ, Stebbins RA, Metz L, Levy JC. Cannabis use as described by people with multiple sclerosis. Can J Neurol Sci 2003;30:201-5.
9. Brenneisen R, Elsohly MA, Henn V, Spiess Y. The effect of orally and rectally administered delta-9-tetrahydrocannabinol on spasticity: a pilot with 2 patients. Int J Clin Pharmacol Ther 1996;34(10):446-52.
10. Clifford DB. Tetrahydrocannabinol for tremor in multiple sclerosis. Ann Neurol 1981;13(6):669-71.
11. Hamann W, di Vadi PP. Analgesic effect of the cannabinold analogue nablione is not mediated by opioid receptors. Lancet 1999;353(9152):560.
12. Fox P, Bain PG, Glickman S, Carroll C, Zajicek J. The effect of cannabis on tremor in patients with multiple sclerosis. Neurology 2004;62:1105-9.
13. Killestein J, Hoogervorst ELJ, Reif M, Kalkers NF, van Loenen AC, Staats PGM, et al. Safety tolerability and efficacy of orally administered cannabinoids in MS. Neurology 2002;58:1404-7.
14. Zajicek J, Fox P, Sanders H, Wright D, Vickery J, Nunn A, et al. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multi-centre randomised placebo-controlled trial, Lancet 2003;362:1517-26.
15. Meinck HM, Schonle PW, Conrad B. Effect of cannabinoids on spasticity and ataxia in multiple sclerosis. J Neurol 1989;236(2):120-2.
16. Schon F, Hart PE, Hodgson TL, Pambakian ALM, Ruprah M, Williamson EM, et al. Suppression of pendular nystagmus by smoking cannabis in a patient with multiple sclerosis. Neurology 1999;53:2209-10.
17. Greenberg HS, Werness SAS, Pugh JE, Andrus RO, Anderson DJ, Domino EF. Short-term effects of smoking marijuana on balance in patients with multiple sclerosis and normal volunteers. Clin Pharmacol Ther 1994;55(3):324-8.
18. Consroe P, Musty R, Rein J, Tillery W, Pertwee R. The perceived effects of smoked cannabis on patients with multiple sclerosis. Eur Neurol 19977;38(1):44-8.
19. Furler MD, Einarson TR, Miltson M, Walmsley S, Bendayan R. Medicinal and recreational marijuana use by patients infected with HIV. AIDS Patient Care STDs 2004;18(4):215-28.
20. Ware MA, Doyle CR, Woods R, Lynch ME, Clark AJ. Cannabis use for chronic non-cancer pain: results of a prospective survey. Pain 2003;102(1-2):211-6.
21. Ware MA, Gamsa A, Persson J, Fitzcharles MA. Cannabis for chronic pain: case series and implications for clinicians Pain Res Manage 2002:7(2):95-9.
22. Page SA, Verhoef MJ, Stebbins RA, Metz L, Levy JC. Complementary and alternative medicine use by people with multiple sclerosis. Chronic Dis Can 2003;24(2/3):75-9.
23. Sandelowski M. Whatever happened to qualitative description? Res Nurs Health 2000;23(4):334-40.
24. The Ethnograph, version 5.0, Thousand Oaks, Calif: Scolari, Sage publications Software, Inc; 1998.
25. Miles MB, Haberman AM. Qualitative data analysis. 2nd ed. Thousand Oaks, Calif: Sage Publications Ltd; 1994.
26. Mays N, Pope C. Rigor and qualitative research. BMJ 1995;311:109-12.
27. Government of Canada. Medical marihuana access regulations SOR/2001-27 pursuant to the Controlled Drugs and Substances Act s.c.1996, c.19. ss55(1). Ottawa, Ont: Government of Canada; 2001.
28. Sibbald B. A primer for patient's use of medical marijuana [news]. CMAJ 2001;165:329.
29. Canadian Medical Association. Canadian Medical Association code of ethics. Ottawa, Ont: Canadian Medical Association; 1996.